Sugi Predict

Sugi Predict / Compounds / SCHEMBL3506743

SCHEMBL3506743

SCHEMBL3506743

CC(C)(C)OC(=O)N1CC(O)(C(F)(F)F)C1

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ PDK2 Q15119 1/20 0.40
▸ NR1H2 P55055 2/20 0.39
▸ CHRM2 P08172 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ HPGD P15428 1/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ RECQL P46063 1/20 0.36
▸ EPHX1 P07099 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ RORC P51449 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23850570 0.86 USP2 (0.40) USP2SMN1; SMN2PDK2NR1H2CHRM2
SCHEMBL4224125 0.86 USP2 (0.44) USP2SMN1; SMN2PDK2HPGDEPHX2
SCHEMBL31158934 0.85 USP2 (0.39) USP2SMN1; SMN2PDK2NR1H2CHRM2
SCHEMBL1091277 0.85 USP2 (0.47) USP2SMN1; SMN2NR1H2CHRM2CHRM1
SCHEMBL2593157 0.84 HPGD (0.42) USP2SMN1; SMN2PDK2HPGDEPHX2
SCHEMBL31158881 0.84 USP2 (0.38) USP2SMN1; SMN2PDK2NR1H2CHRM2
SCHEMBL2706445 0.82 USP2 (0.50) USP2SMN1; SMN2PDK2HPGDEPHX2
SCHEMBL31716895 0.80 USP2 (0.43) USP2SMN1; SMN2PDK2NR1H2CHRM2
SCHEMBL12102911 0.79 USP2 (0.42) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL2957192 0.79 NR1H2 (0.44) USP2SMN1; SMN2NR1H2HPGDEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025111582-A1 AZA-TETRACYCLIC OXAZEPINE INHIBITORS OF KRAS-G12D GENENTECH, INC. (US) 2025-05-30 — — WO disclosed
EP-3837263-B1 NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN LA ROCHE (CH) 2024-07-03 — — EP disclosed
CN-118119629-A Nitrogen-containing heterocyclic compound and medical application thereof 中国医药研究开发中心有限公司 2024-05-31 — — CN disclosed
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES CILAG AG (CH) 2024-05-30 — — US disclosed
US-20240150373-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2024-05-09 — — US disclosed
WO-2024067691-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF 中国医药研究开发中心有限公司 2024-04-04 — — WO disclosed
CN-115403584-B 2-thio-2, 3-dihydropyrimidine-4-one derivatives, pharmaceutical compositions, preparation methods and applications thereof 长春金赛药业有限责任公司 2024-04-02 — — CN disclosed
EP-4284802-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES Janssen Biotech, Inc. (US) 2023-12-06 — — EP disclosed
US-11802133-B2 Heterocyclic compounds as monoacylglycerol lipase inhibitors HOFFMANN-LA ROCHE INC. (US) 2023-10-31 — — US disclosed
US-11731943-B2 Therapeutic compounds, compositions and methods of use thereof GENENTECH, INC. (US) 2023-08-22 — — US disclosed
US-20190071404-A1 THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2019-03-07 — — US disclosed
US-20190071404-A1 THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2019-03-07 — — US disclosed
WO-2017191098-A1 PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2017-11-09 — — WO disclosed
WO-2017191098-A1 PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2017-11-09 — — WO disclosed
EP-2211620-B1 3-PYRAZIN SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AS JANUS KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES MERCK SHARP & DOHME (US) 2013-12-25 — — EP disclosed
US-8183245-B2 Pyrazine substituted pyrrolopyridines as inhibitors of JAK and PDK1 MERCK SHARP & DOHME CORP. (US) 2012-05-22 — — US disclosed
US-20100210623-A1 THERAPEUTIC COMPOUNDS MERCK SHARP & DOHME CORP. 2010-08-19 — — US disclosed
EP-2211620-A1 THERAPEUTIC COMPOUNDS Merck Sharp & Dohme Corp. (US) 2010-08-04 — — EP disclosed
WO-2009054941-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2009-04-30 — — WO disclosed
WO-2002012187-A1 NOVEL PHENYLHETEROAZETIDINES, USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS ASTRAZENECA AB (SE) 2002-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210623-A1 THERAPEUTIC COMPOUNDS JAK2, PDK1, JAK3 USP2 3073/4885SMN1; SMN2 3959/4885PDK2 7/4885
US-20190071404-A1 THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF JAK2, JAK1, JAK3 USP2 3172/4885SMN1; SMN2 2581/4885PDK2 895/4885
US-20240150373-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS LIPC, LPL, MGLL USP2 635/4885SMN1; SMN2 3927/4885PDK2 1395/4885
US-11731943-B2 Therapeutic compounds, compositions and methods of use thereof JAK2, JAK1, JAK3 USP2 3172/4885SMN1; SMN2 2581/4885PDK2 895/4885
US-11802133-B2 Heterocyclic compounds as monoacylglycerol lipase inhibitors LIPC, LPL, MGLL USP2 635/4885SMN1; SMN2 3927/4885PDK2 1395/4885
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES SIK2, SIK1, SGK2 USP2 2482/4885SMN1; SMN2 3406/4885PDK2 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.